Pre‐clinical studies in transplantable tumour models—such as murine B16 F10 melanoma and human breast cancer xenografts—have demonstrated that ORFV treatment can slow tumour growth by enhancing NK cell cytotoxicity and increasing IFN‐γ secretion. Here, IFNG is linked to neoplasm.